Infusion Laboratory: Protocol 5 (Flupenthixol) - 14

National Institutes of Health (NIH) logo

National Institutes of Health (NIH)

Status and phase

Unknown
Phase 1

Conditions

Cocaine-Related Disorders

Treatments

Drug: Flupenthixol

Study type

Interventional

Funder types

NIH

Identifiers

NCT00000349
NIDA-3-0010-14
Y01-3-0010-14

Details and patient eligibility

About

The purpose of this study is to evaluate clinical safety issues pertaining to flupenthixol, to cocaine, and to their interaction, and to determine how pretreatment with flupenthixol modifies the subjective as well as physiological effects of cocaine. Taken together, these relatively D-1 selective agents can help determine the extent to which DA-1 binding affects the reinforcing effects of stimulants.

Sex

All

Ages

21 to 50 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

M/F, ages 21-50. Meet DSM-IV criteria for cocaine dependence. Agree to conditions of the study and sign informed consent.

Exclusion criteria

Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nuring women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics. Acute hepatitis. Other medical condtions that deem participation to be unsafe.

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems